Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ADGRF1 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRF1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRD2 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor D2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRD2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRA3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor A3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRA2 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor A2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAMTS7 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADAMTS7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAMTS12 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADAMTS12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PAQR6 Biologics Sequence Review Report 2026: Membrane progestin receptor delta Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PAQR6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SELENOP Biologics Sequence Review Report 2026: Selenoprotein P Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SELENOP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NELL2 Biologics Sequence Review Report 2026: Protein kinase C-binding protein NELL2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NELL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NELL1 Biologics Sequence Review Report 2026: Protein kinase C-binding protein NELL1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NELL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCRLB Biologics Sequence Review Report 2026: Fc receptor-like B Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRLB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCRLA Biologics Sequence Review Report 2026: Fc receptor-like A Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRLA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.